Consonance Capital Management as of March 31, 2015
Portfolio Holdings for Consonance Capital Management
Consonance Capital Management holds 27 positions in its portfolio as reported in the March 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | 11.2 | $123M | 712k | 172.44 | |
| Akorn | 8.4 | $92M | 1.9M | 47.51 | |
| Hyperion Therapeutics | 8.0 | $87M | 1.9M | 45.90 | |
| Cardiovascular Systems | 7.8 | $86M | 2.2M | 39.04 | |
| Insys Therapeutics | 7.2 | $79M | 1.4M | 58.13 | |
| Retrophin | 6.8 | $75M | 3.1M | 23.96 | |
| Biosante Pharmaceuticals (ANIP) | 6.4 | $70M | 1.1M | 62.55 | |
| Abbvie (ABBV) | 6.3 | $69M | 1.2M | 58.54 | |
| Orthofix International Nv Com Stk | 5.2 | $57M | 1.6M | 35.89 | |
| Anacor Pharmaceuticals In | 4.4 | $48M | 830k | 57.85 | |
| Enanta Pharmaceuticals (ENTA) | 4.3 | $48M | 1.6M | 30.62 | |
| Supernus Pharmaceuticals (SUPN) | 3.9 | $43M | 3.6M | 12.09 | |
| Pernix Therapeutics Holdings | 3.2 | $35M | 3.3M | 10.69 | |
| Healthways | 3.1 | $34M | 1.7M | 19.70 | |
| Eagle Pharmaceuticals (EGRX) | 2.8 | $31M | 736k | 41.89 | |
| Osiris Therapeutics | 1.9 | $21M | 1.2M | 17.58 | |
| Catalyst Pharmaceutical Partners (CPRX) | 1.9 | $21M | 4.8M | 4.33 | |
| Derma Sciences | 1.3 | $14M | 1.6M | 8.47 | |
| Epirus Biopharmaceuticals In | 1.2 | $14M | 1.5M | 8.95 | |
| Pacific Biosciences of California (PACB) | 1.1 | $12M | 2.0M | 5.84 | |
| Protalix BioTherapeutics | 0.9 | $10M | 5.6M | 1.78 | |
| Adma Biologics (ADMA) | 0.9 | $9.7M | 987k | 9.80 | |
| Vericel (VCEL) | 0.8 | $8.7M | 2.4M | 3.70 | |
| BioTime | 0.7 | $8.0M | 1.6M | 4.97 | |
| Merus Labs Intl | 0.3 | $2.9M | 1.4M | 2.10 | |
| Veracyte (VCYT) | 0.2 | $1.7M | 236k | 7.28 | |
| eHealth (EHTH) | 0.1 | $496k | 53k | 9.38 |
